Amylyx Pharmaceuticals, Inc. 4

Chief Legal Officer Gina Mazzariello sold 30,000 shares of Amylyx Pharmaceuticals, Inc. (AMLX) common stock over two days in open market transactions under a Rule 10b5-1 plan.

On July 9 and 10, 2026, Amylyx Pharmaceuticals, Inc. Chief Legal Officer Gina Mazzariello sold a total of 30,000 shares of Amylyx common stock under a pre-arranged Rule 10b5-1 trading plan adopted on April 9, 2026, at weighted average prices of $18.3164 and $17.6081, respectively, for aggregate proceeds of roughly $540,000. Following these open market sales, which were executed in multiple transactions within disclosed price ranges, Mazzariello’s direct holdings decreased from 209,090 shares prior to the first sale to 179,090 shares, leaving a still-substantial continuing equity stake in the company.

Filing Facts

CIK

1658551

Ticker

AMLX

Form

4

Source Type

fda

Accession

0001193125-26-301996

Alert Tier

6